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Functional characterization of 
ipsC-derived arterial- and  
venous-like endothelial cells
s. Rosa1, C. praça1,4, p. R. pitrez  1,4, p. José Gouveia1,2, X. L. Aranguren5, L. Ricotti3 & 
L. silva Ferreira1,4
the current work reports the functional characterization of human induced pluripotent stem cells 
(iPSCs)- arterial and venous-like endothelial cells (ECs), derived in chemically defined conditions, 
either in monoculture or seeded in a scaffold with mechanical properties similar to blood vessels. iPSC-
derived arterial- and venous-like endothelial cells were obtained in two steps: differentiation of iPSCs 
into endothelial precursor cells (CD31pos/KDRpos/Ve-Cadmed/EphB2neg/CoUp-tFneg) followed by their 
differentiation into arterial and venous-like ECs using a high and low vascular endothelial growth factor 
(VeGF) concentration. Cells were characterized at gene, protein and functional levels. Functionally, 
both arterial and venous-like iPSC-derived ECs responded to vasoactive agonists such as thrombin 
and prostaglandin E2 (PGE2), similar to somatic eCs; however, arterial-like ipsC-derived eCs produced 
higher nitric oxide (No) and elongation to shear stress than venous-like ipsC-derived eCs. Both cells 
adhered, proliferated and prevented platelet activation when seeded in poly(caprolactone) scaffolds. 
Interestingly, both iPSC-derived ECs cultured in monoculture or in a scaffold showed a different 
inflammatory profile than somatic ECs. Although both somatic and iPSC-derived ECs responded to 
tumor necrosis factor-α (tNF-α) by an increase in the expression of intercellular adhesion molecule 
1 (ICAM-1), only somatic ECs showed an upregulation in the expression of E-selectin or vascular cell 
adhesion molecule 1 (VCAM-1).
Ischemic cardiovascular diseases (CVD) significantly impair quality of life being one of the leading causes of 
morbidity and mortality in industrialized countries1. Current treatments for CVD include pharmacological treat-
ments and vascular surgeries; however, they show limited efficacy. As alternative, cell-based therapies are under 
investigation2. Cell-based therapies aim to replace dysfunctional vascular cells and promote the growth and repair 
of blood vessels. These therapies are also being investigated in the treatment of diabetic foot ulcers and peripheral 
vascular diseases, as these patients have microvascular complications and dysfunctional vascular cells2.
iPSCs are a relevant source of vascular cells since they have the ability to give rise to an unlimited number 
of ECs2–6. Patient-specific iPSC-derived ECs can constitute a source of autologous cells for several applications 
for the treatment of CVD, alone or in combination with a scaffold. iPSC-derived ECs are able to form functional 
blood vessels after transplantation on mouse animal models4–7 and zebrafish embryos8. ECs have now been dif-
ferentiated using a variety of strategies and protocols (reviewed in9 and10). Some studies attempted to characterize 
but not to control the endothelial sub-phenotype8,11.
The specification of these ECs is of utmost importance for the use of these cells for regenerative medicine 
applications9,10. It is desirable that venous and arterial ECs will have different use according to the final appli-
cation (e.g. grafts, patches or vascularization protocols) and tissue of engraftment. In the last 10 years, studies 
have documented the specification of ECs into venous and arterial ECs6,12–17. The first studies have differentiated 
endothelial progenitor cells into arterial and venous cells in the presence of non-defined media (i.e. containing 
serum). For example, iPSC-derived Flk1+ cells were differentiated into arterial and venous ECs by the modulation 
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of cAMP and VEGF signaling pathways18. Flk1+ cells differentiated into venous and arterial cells after activation 
of VEGF or both VEGF and cAMP pathways, respectively. Others have differentiated iPSCs into arterial and 
venous ECs without the use of endothelial progenitor cells by manipulating the same signaling pathways12. More 
recently, studies have reported the generation of arterial and venous ECs from iPSCs in defined media6,13,16. In 
most cases, more than one signaling pathways have been manipulated to specify the sub-phenotype of ECs13,16. 
Only one study6 has documented the derivation of arterial and vein ECs by the control of a single signaling path-
way (VEGF); however, no clear indication about the specification yield and stability of the derived cells was given. 
Despite the advances in the specification of iPSC-derived ECs, the functional properties of these sub-phenotypes 
have not been fully determined. Another issue not investigated is the functional properties of these iPSC-derived 
ECs after culture in scaffolds. Several scaffolds have been developed for the transplantation of iPSC-derived 
ECs4,19,20; however, in most cases, with mechanical properties different from native blood vessels (i.e. elastic mod-
ulus between 0.1 and 1 MPa21,22). Differences in mechanical compliance have been shown to increase the risk of 
thrombosis23 and intimal hyperplasia24.
Herein, we differentiated iPSC- derived EC precursor cells into arterial and venous-like ECs in 
chemically-defined conditions, modulating a single signaling pathway, i.e. VEGF. The derived cells were char-
acterized at gene and protein levels. Our results showed that arterial-like ECs are closer to HUAECs while 
venous-like ECs closer to HUVECs. These cells were further characterized at functional level either in mono-
culture or seeded in scaffolds with elastic modulus values close to the native blood vessels. Our results indicated 
that both cells (i) responded to pro-inflammatory stimuli such as tumor necrosis factor-α (TNF-α), but at a 
lower extent than somatic ECs; (ii) responded to vasoactive agonists such as thrombin and prostaglandin E2 
(PGE2), similarly to somatic ECs; (iii) responded differently to shear stress (arterial-like ECs more elongated 
than venous-like ECs); (iv) produced differently nitric oxide (arterial-like ECs more than venous-like ECs); (v) 
adhered, proliferated and formed a cell monolayer after seeding in scaffolds; and (vi) the cell monolayer did not 
induce platelet activation.
Results
Differentiation of hiPSCs into ECs in chemically-defined and serum-free conditions. hiPSCs 
were initially differentiated into mesoderm progenitors (Brachyurypos)25 followed by their differentiation into 
endothelial precursor cells (EPCs) that expressed residual levels of venous (e.g. COUP-TFII)26 and arterial (e.g. 
EphB2, receptor of ephrin B2)27 markers. To obtain mesoderm progenitors, undifferentiated cells were cultured 
with chemically defined medium (CDM; without serum)28 supplemented with 10 ng/ml BMP4 and 20 ng/ml 
FGF-β for 1.5 days and then 50 ng/ml BMP4 with 20 ng/ml FGF-β until day 5 (Supplementary Fig. S1). The mes-
oderm progenitors were further differentiated into EPCs by culturing the cells in media containing VEGF and 
Tβ4, known to be important for endothelial differentiation3 from day 5 until day 10. As control, iPSCs were also 
differentiated in CDM without supplements. The expression of mesoderm (Brachyury) and endothelial (CD31, 
KDR and VE-cadherin) mRNA transcripts during cell differentiation was evaluated by qRT-PCR analyses. The 
expression of Brachyury peaked at day 4 (Supplementary Fig. S1), KDR and VE-cadherin peaked at day 8, and 
the highest level of CD31 expression was observed at day 10 (Supplementary Fig. S1). In all cases the expression 
of mesoderm and EC markers was higher in cells cultured in CDM inductive media (CDMi) than CDM without 
supplements. To supplement the previous results, the expression of EC markers CD31 and KDR was analyzed by 
flow cytometry (Supplementary Fig. S1). At the beginning of the differentiation there was a residual expression 
of CD31 (1.0 ± 0. 2%) and low levels of KDR (10.6 ± 0.5%). The percentage of cells expressing both markers 
increased overtime (at least for 10 days) and was higher in cells differentiated in CDMi than in CDM without 
supplements. Cells at day 10 had an EC-like morphology and expressed CD31 at cell junctions as confirmed by 
immunostaining (Supplementary Fig. S2). Based on EC expression profile we isolated CD31+ cells as EPCs.
EPCs expressed general EC markers including CD31 and KDR; however, only 21.6 ± 2.4% of the cells 
were positive for the late EC marker, VE-cadherin, as quantified by flow cytometry (Supplementary Fig. S1). 
In addition, EPCs expressed residual levels of arterial marker EphB2 (2.0 ± 0.3%) and the venous marker 
COUP-TFII (2.4 ± 0.5%) as compared to HUAECs (EphB2: 35 ± 7.9%) and HUVECs (COUP-TFII: 92.5 ± 0.9%) 
(Supplementary Figs S1 and S2). Similarly, qRT-PCR data showed that EPCs had significantly lower levels of the 
venous markers EphB4 than HUVECs and HUAECs (Supplementary Fig. S2). Overall, results suggest that our 
EPCs do not have yet a defined endothelial sub-phenotype.
Derivation and characterization of arterial endothelial-like cells (AeLCs). EPCs were cultured in 
EC-serum-free medium supplemented with a high concentration of VEGF (50 ng/ml) for 4 passages (P0 to P4) 
(Fig. 1a). At gene level, iPSC-derived ECs (P4) expressed similar or higher mRNA levels of CD31, VE-cadherin 
and KDR than HUAECs (Fig. 1b). At protein level, the percentage of cells expressing CD31 and KDR was similar 
at P0 and P4 (CD31: 92.0 ± 3.3% to 88.3 ± 4.2%; KDR: 90.8 ± 2.5% to 89.3 ± 5.2%) while the percentage of cells 
expressing VE-cadherin increased significantly in cells from P0 to P4 (from 21.6 ± 2.4% at P0 to 92.3 ± 1.4% at 
P4) indicating a maturation process (Supplementary Fig. S1). This was further confirmed by a high percentage of 
cells expressing vWF (93.8 ± 0.1%) (Fig. 1c). Immunofluorescence results further confirmed that iPSC-derived 
ECs expressed CD31, KDR, VE-cadherin and vWF (Fig. 1d). At the functional level, these cells (P4) had the abil-
ity to uptake acetylated low-density-lipoprotein (Ac-LDL) (Fig. 1d and Supplementary Fig. S2) and form capillary 
like-networks on Matrigel (Fig. 1d and Supplementary Fig. S3).
Next, we evaluated the expression of arterial and venous markers in iPSC-derived ECs (P4). Increased expres-
sion of members of Notch canonical signaling pathway, including NOTCH4, JAG1, HEY2, EFNB1, EFNB2, DLL4 
and CXCR4 genes are associated with an arterial phenotype10,29. Conversely, increased expression of NR2F2 and 
EphB4 have been shown to be more restricted to the venous endothelium26,30. Gene expression analyses indi-
cated that iPSC-derived ECs expressed higher levels of arterial markers than HUVECs or even HUAECs (Fig. 1e 
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and Supplementary Fig. S4). In addition, cells expressed less NR2F2 and EphB4 than HUVECs (Fig. 1f). These 
results have been confirmed at protein level. Approximately 27% and 100% of iPSC-derived ECs (P4) expressed 
EphB2 (receptor of ephrin B2) and EphrB2 (ephrin B2 ligand), respectively, near the cell percentages observed 
in HUAECs (Fig. 1g, Supplementary Fig. S2). As expected, a very low percentage of iPSC-derived ECs (P4) 
expressed the venous marker COUP-TFII (ca. 15%) (Fig. 1h and Supplementary Fig. S2). Importantly, the arterial 
Figure 1. Derivation and characterization of AELCs. (a) Schematic representation of the protocol. EPCs were 
cultured in serum free medium supplemented with VEGF (50 ng/ml) for 10–15 days (4 passages). (b) qRT-PCR 
of general EC markers. Results were normalized by GAPDH and expressed relatively to HUAECs (n = 4). (c) FC 
analyses of EC markers (n = 3). (d) Expression and localization of general (CD31, KDR, VE-cadherin, vWF) as 
well as EC specification markers (COUP-TFII and Ephrin B2) by immunofluorescence. Functional activity of 
ECs as measured by their capacity to form cord-like structures in Matrigel and incorporate ac-LDL. (e) qRT-
PCR of arterial markers (n = 4). Data was normalized by GAPDH and expressed relatively to HUAECs. (f) qRT-
PCR of venous markers (n = 6). Data was normalized by GAPDH and expressed relatively to HUVECs. (g) Flow 
cytometry analyses of the arterial marker EphB2 (n = 3). (h) Quantification of the nuclei positive for COUP-
TFII. Images were acquired in 6 different fields that contained an average of 300 cells. In (e,f,g and h) statistical 
analyses was performed by Kruskal-Wallis test followed by a Dunn’s multiple comparisons test. *p < 0.5, 
**p < 0.1, ***p < 0.001, ****p < 0.0001. Results are mean ± SEM.
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phenotype in iPSC-derived ECs was maintained for at least 9 passages, as evaluated by the percentage of EphB2 
positive cells (Supplementary Fig. S4). To confirm that the differentiation protocol was extensive to other human 
pluripotent stem cells, human embryonic stem cells (hESCs) were used. Similar to iPSCs, increased expression of 
arterial genes was obtained in hESC-derived ECs (Supplementary Fig. S5). Taken together, based in the general 
expression of EC markers, expression of arterial markers and EC functional activity, the cells were named as 
AELCs. Our results show that EPCs cultured in EC-serum-free medium supplemented with a high concentration 
of VEGF gave rise to AELCs. From 1 million undifferentiated iPSCs we obtained approximately 7.5 million of 
AELCs after 20 days of differentiation.
Derivation and characterization of venous endothelial-like cells (VeLCs). EPCs were cultured in 
EC-serum-free medium supplemented with a low concentration of VEGF (10 ng/ml) for 4 passages (P0 to P4) 
(Fig. 2a). At gene level, iPSC-derived ECs (P4) expressed similar mRNA levels of CD31, KDR and VE-cadherin 
than HUVECs (Fig. 2b). At protein level, the expression of CD31 and KDR slightly decreased from P0 to P4 
(CD31: 92.0 ± 3.3% to 84.1 ± 4%; KDR: 90.8 ± 2.5% to 80.8 ± 5%) while the expression of VE-cadherin increased 
significantly (from 21.6 ± 2.4% at P0 to 89.9 ± 2.5% at P4). At P4, approximately 81% of the cells were posi-
tive for vWF, indicating an EC maturation process (Fig. 2c). Immunofluorescence results further confirmed that 
iPSC-derived ECs expressed CD31, KDR, VE-cadherin and vWF (Fig. 2d). At the functional level, iPSC-derived 
ECs (P4) had the capacity to uptake Ac-LDL (Fig. 2d and Supplementary Fig. S2) and to form a capillary 
like-network on top of Matrigel (Fig. 2d and Supplementary Fig. S3).
Next, we evaluated the expression of arterial and venous markers in iPSC-derived ECs. These cells (P4) showed 
high mRNA expression of the venous marker NR2F2 and EphB4 (Fig. 2e) and low mRNA expression of the arte-
rial markers HEY2, EFNB1, EFNB2, JAG1 DLL4 and CXCR4 as compared to HUAECs (Fig. 2f and Supplementary 
Fig. S4). At protein level, the percentage of iPSC-derived ECs (P4) expressing COUP-TFII and EphB2/Ephrin B2 
was ca. 55% and 0% (Fig. 2d,g,h and Supplementary Fig. S2). The percentage of COUP-TFII positive cells was sig-
nificantly higher than the one found for EPCs (1.1 ± 0.3%) and AELCs (15 ± 1.2%) but lower than the one found 
for HUVECs (92.5 ± 0.9%). The venous specification of iPSC-derived ECs was maintained for at least 9 passages 
as evaluated by the percentage of COUP-TFII positive cells that was similar to P4 cells (Supplementary Fig. S5). 
To confirm that the differentiation protocol was extensive to other human pluripotent stem cells, hESCs were 
used. Similar to iPSCs, increased expression of venous genes was obtained in hESC-derived ECs (Supplementary 
Fig. S6). Taken together, based on the general expression of EC markers, expression of venous markers and 
EC functional activity, the cells were named as VELCs. Our results show that EPCs cultured in EC-serum-free 
medium supplemented with a low concentration of VEGF gave rise to VELCs. From 1 million undifferentiated 
iPSCs we obtained approximately 7.5 million of VELCs after 20 days of differentiation.
Functional characterization of AeLCs and VeLCs in monoculture. We asked whether AELCs or 
VELCs could respond to pro-inflammatory stimuli such as TNF-α by assessing the expression of adhesion mol-
ecules such as E-selectin, ICAM-1 and VCAM-1. The expression of these adhesion molecules is critical for the 
adhesion of monocytes to ECs31. Cells were treated with TNF-α (10 ng/ml) for 24 h and the expression of adhe-
sion molecules monitored by flow cytometry. Both AELCs and VELCs showed an up-regulation in the expression 
of ICAM-1 as observed for HUAECs and HUVECs (Fig. 3a). The mean fluorescence intensity (MFI), as assessed 
by flow cytometry, was higher in VELCs than in AELCs, similarly to what was observed in HUVECs versus 
HUAECs. Similar trend was observed at gene level (Supplementary Fig. S7). Interestingly, a relatively low percent-
age of AELCs and VELCs expressed E-Selectin and VCAM-1 in response to TNF- α in comparison with HUAECs 
and HUVECs, suggesting a certain degree of immaturity in our iPSC-derived ECs (Fig. 3a).
Since ECs were activated by pro-inflammatory cytokines we complemented the previous results with a 
monocyte-EC adhesion assay to determine whether adhesion molecules were functional in mediating monocyte 
adhesion to ECs and to determine whether this activity was different between arterial and venous ECs31,32. For that 
purpose, cells were treated with TNF-α (10 ng/ml) for 6 h, washed, co-cultured with monocytes fluorescently labe-
led for 30 min and the unbound monocytes removed by washing. Our results showed that the adhesion of THP1 
cells to TNF-α-treated AELCs or VELCs was higher than non-treated ECs (Fig. 3b). Yet, the percentage of adherent 
THP1 cells in TNF-α-treated AELCs or VELCs was lower than the one observed in TNF-α-treated HUVECs or 
HUAECs. It is likely that the lower adhesion of THP1 in TNF-α-treated AELCs and VELCs was related to the lower 
expression of E-Selectin and VCAM-1 as the one observed in TNF-α-treated HUAECs and HUVECs.
A general property of ECs is their ability to respond to vasoactive agents and to rearrange junctional and 
cytoskeletal proteins in response to physiological stimulus to maintain a tight dynamic barrier33. Indeed, AELCs 
and VELCs responded to the vasoactive agonists such as thrombin and PGE2, similar to HUVECs or HUAECs, by 
increasing the intracellular levels of Ca2+ (Fig. 3c). As a consequence, both AELC and VELC monolayers showed 
a decrease or increase in basal trans-endothelial electrical resistance (TEER) levels in case they were stimulated 
with thrombin or PGE2, respectively (Fig. 3d).
Arterial and venous ECs show different activities regarding, NO production and elongation to shear stress13. 
Our results showed that AELCs and HUAECs had higher elongation, particularly to high shear stress (e.g. 12 dyn/
cm2), than VELCs or HUVECs (Fig. 4a.1a.2). Moreover, the NO production was higher on AELCs than VELCs, 
and thus explaining the fact that AELCs had lower monocyte adhesion than VELCs (NO prevents monocyte 
adhesion) (Fig. 4c).
Overall, our results show that AELCs and VELCs respond to vasoactive agents such as thrombin and PGE2 
as somatic ECs including HUVECs and HUAECs; however, they show a lower pro-inflammatory response to 
TNF-α than somatic HUVECs or HUAECs. Our results further demonstrate that AELCs produced higher NO 
and elongation to shear stress than VELCs.
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Functional characterization of AELCs and VELCs in a scaffold with mechanical properties simi-
lar to blood vessels. The scaffolds prepared in this work (screened from different polymers and concentra-
tions) were based on stable ultrathin polymeric nanofilms. Nanofilms were prepared from degradable polymers, 
including poly(L-lactic acid) (PLLA) and poly(caprolactone) (PCL), and non-degradable polymers such as 
Figure 2. Derivation and characterization of VELCs. (a) Schematic representation of the protocol. The EPCs were 
cultured in serum free medium supplemented with VEGF (10 ng/ml) for 10–15 days (4 passages). (b) qRT-PCR of 
general EC markers. Data were normalized by GAPDH and expressed relatively to HUVECs (n = 4). (c) FC analyses 
of EC markers (n = 3). (d) Expression and localization of general (CD31, KDR, VE-cadherin, vWF) and specification 
EC markers (COUP-TFII and Ephrin B2) by immunofluorescence. Functional activity of ECs measured by their 
capacity to form cord-like structures in Matrigel and incorporate ac-LDL. (e) qRT-PCR for venous markers. Data 
was normalized by GAPDH and expressed relatively to HUVECs (n = 3). (f) qRT-PCR of arterial markers. Data were 
normalized by GAPDH and expressed relatively to HUAECs (n = 3). (g) Quantification of COUP-TFII. Images were 
acquired in 6 different fields that contained an average of 300 cells. (h) Flow cytometry analyses of the arterial marker 
EphB2 in ECs (n = 3). In (e–h) statistical analyses were performed by Kruskal-Wallis test followed by a Dunn’s 
multiple comparisons test. *p < 0.5, **p < 0.1, ***p < 0.001, ****p < 0.0001. Results are mean ± SEM.
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poly(dimethylsiloxane) PDMS (Supplementary Fig. S8). PCL was chosen because in vivo studies have demon-
strated that PCL scaffolds are suitable to engineer blood vessels34–36. PDMS and PLLA have also been used in 
several biomedical applications and they allow EC adhesion and proliferation37,38. Nanofilms were prepared with 
Figure 3. Functional characterization of AELCs and VELCs. (a) Flow cytometry analyses of adhesion 
molecules in ECs before and after exposure to TNF-α (10 ng/ml) for 24 h (n = 3). (b) EC monolayers treated or 
not with TNF-α (10 ng/ml) for 6 h were co-cultured for 30 min with CSFE labeled THP1. Number of adherent 
THP1 cells was counted and expressed as percentage relative to the total number of nuclei (ECs and THP1). 
Representative images for the adhesion of THP1 cells are shown (n = 3). (c) Variation of intracellular Ca2+ 
in FURA-2-loaded ECs in response to thrombin and PGE2. Traces are representative of 6 replicas for each 
condition. (d) Changes in TEER of cells treated with thrombin or PGE2 (n = 3). In (b) statistical analyses were 
performed by a Mann-Whitney test. In (d) statistical analyses were performed by a Kruskal Wallis test followed 
by a Dunn’s multiple comparisons test. Statistical significance in each time point is relatively to the initial time 
point (time 0). *p < 0.5, **p < 0.1, ***p < 0.001, p**** < 0.0001. Results are mean ± SEM.
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an area of 2 × 2.5 cm2 and with a thickness between 40 and 60 nm (Supplementary Fig. S8) as measured by atomic 
force microscopy (AFM). As evaluated by traction tests, the nanofilm elastic modulus ranged between 0.98 ± 0.4 
and 16.5 ± 3.1 MPa for PCL, 0.2 ± 0.02 and 0.9 ± 0.06 MPa for PDMS and 1.4 ± 0.3 to 31.2 ± 8.9 MPa for PLLA, 
respectively (Supplementary Fig. S8). Based on the mechanical properties we selected PCL (10 mg/mL) and 
PDMS (1/10) nanofilms for further analyses because the elastic modulus was in the range observed in arteries, 
and because the PLLA nanofilms with low elastic modulus were very fragile and often crashed during manipula-
tion. As measured by AFM, the average surface roughness (Ra) of PCL and PDMS nanofilms was 0.007 ± 0.0004 
μm and 0.01 ± 0.002 μm, respectively (Supplementary Fig. S8).
Nanofilms were mounted in a cell culture insert that kept the nanofilms immobilized during cell culture 
(Fig. 5a). Cell adhesion in PDMS nanofilms and PCL nanofilms was quantified 4 h after cell seeding by quantify-
ing the number of Hoechst positive nuclei. Our results showed that approximately 60–70% of the cells adhered 
to PCL and PDMS nanofilms, relatively to TCPS condition (Fig. 5b). These cells were viable as assessed by a 
Presto Blue assay (Fig. 5c). Cell proliferation results, obtained by the ratio of cell viability (Presto Blue assay) at 
72 h and 4 h, showed that all cell types proliferated similarly in both PCL and PDMS nanofilms (Fig. 5d). The 
iPSC-derived AELCs and VELCs cultured for 72 h on top of the nanofilms were able to form a monolayer and 
they expressed VE-cadherin and ZO-1 (Fig. 5e). We found a significant higher VE-cadherin intensity for both 
VELCs and AELCs cultured for 3 days in PCL nanofilms in comparison with VELCs and AELCs cultured in 
PDMS nanofilms (Supplementary Fig. S9).
Since scaffold modulus can alter the immunogenicity of ECs39, we evaluated the expression of ICAM-1, 
E-selectin and VCAM-1 in ECs cultured on top of the nanofilms. VCAM-1 mRNA levels were below the detection 
Figure 4. Functional characterization of iPSCs-derived AELCs and VELCs. (a.1) Representative images of 
AELCs or VELCs cultured under flow shear stress values for 24 h. Cells were stained for VE-cadherin. (a.2) 
Elongation ratio (calculated by the ratio of cell length to width) of AELCs, VELCs, HUAECs and HUVECs 
cultured under different flow shear stress values for 24 h. Quantifications were done in 3 microfluidic systems 
per experimental condition (approximately 150 cells were counted per each microfluidic system). Statistical 
analyses were performed using a Kruskal-Wallis test, followed by a Dunn’s multiple comparisons test. (b) 
Nitric Oxide (NO) production on AELCs, VELCs, HUVECs and HCAECs was measured using the probe 
DAF-FM. DAF-FM is non-fluorescent until it reacts with NO forming benzotriazole, a fluorescent compound. 
Fluorescence intensity was analyzed by flow cytometry. In (a–c) results are mean ± SEM, n = 3. *p < 0.5, 
**p < 0.1, ***p < 0.001, p**** < 0.0001.
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Figure 5. Characterization of EC- nanofilm interactions. (a) Schematic representation of the assembly of the 
nanofilms onto the cell crown before cell seeding. (b) Cell adhesion to the different substrates. Cell number 
per substrate was quantified at 4 h after cell seeding. Images were taken from 6 random fields by condition. 
Each condition was performed in triplicate (n = 3). (c) Cell viability. Cell viability was assessed at time 4 h after 
seeding, using Presto Blue assay. Each condition was performed in triplicate (n = 3). (d) Cell proliferation. Cell 
proliferation in each substrate was calculated by dividing the fluorescence intensity at 72 h by the one at 4 h. (e) 
Expression and localization of EC markers in AELCs and VELCs cultured on top of nanofilms for 3 days. In 
(b–d) statistical analyses were performed by Kruskal Wallis test followed by a Dunn’s multiple comparisons test. 
*p < 0.5, **p < 0.1, ***p < 0.001, p**** < 0.0001. Results are mean ± SEM.
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limits for all the cells analyzed (data not shown). ICAM-1 and E-selectin mRNA levels were altered in HUVECs 
after culture on PDMS and PCL nanofilms (up-regulation) and VELCs after culture in PCL and PDMS nanofilms 
(down-regulation) (Fig. 6a).
Next, we evaluated whether the inflammatory response of cells cultured on both nanofilms was affected 
after exposure to TNF-α for 6 h. ICAM1 and E-selectin mRNA levels in TNF-α- activated cells were assessed 
by qRT-PCR and normalized by the ones in non-treated cells. A significant up-regulation of ICAM-1 and 
E-selectin mRNA levels was observed for all conditions. However, the up-regulation of E-selectin mRNA levels 
in TNF-α-treated AELCs or VELCs were lower than the ones observed in HUVECs or HUAECs (Fig. 6b). These 
results are in line with the results in Fig. 3a.
To further confirm the inflammatory response profile of cells cultured on nanofilms we quantified the expres-
sion of ICAM-1 and E-selectin by flow cytometry. Cells were cultured in PCL or PDMS nanofilms and tissue cul-
tured polystyrene (as control) and then treated with TNF-α for 24 h. Flow cytometry results show that HUVECs, 
AELCs and VELCs cultured on the nanofilms expressed similar basal levels of ICAM-1 protein as the ones cul-
tured in TCPS (Fig. 6c and Supplementary Fig. S9). Therefore, the increased ICAM-1 mRNA levels observed 
in HUVECs cultured on PCL and PDMS nanofilms (Fig. 6a) were not correlated with a high ICAM-1 protein 
expression, at least after 24 h. TNF-α activated HUVECs, VELCs, HUAECs and AELCs express similar ICAM-1 
levels regardless of the substrate (Fig. 6c). Regarding E-selectin, TNF-α-activated AELCs and VELCs cultured in 
the nanofilms or TCPS expressed negligible (below 4%) values of E-selectin (Supplementary Fig. S10). In contrast, 
TNF-α-activated HUVECs or HUAECs cultured in the nanofilms or TCPS expressed high values of E-selectin 
(approximately 50 to 60% of the cells). Overall, our results show that cell culture onto nanofilms did not change 
significantly basal ICAM-1 and E-selectin expression. In addition, we found that cells respond to TNF-α regard-
less of the substrate in which they were cultured; however, with different magnitude. The results indicate that 
iPSC-derived ECs have a lower inflammatory profile in response to TNF-α than HUVECs or HUAECs.
The hemocompatibility of the nanofilms seeded with iPSC-derived ECs was evaluated by a platelet activation 
assay. For these tests, we have used PCL nanofilms, AELCs, and PCL nanofilms seeded with AELCs. We have 
chosen PCL rather than PDMS nanofilms for these analyses because PCL nanofilms had a better performance in 
maintaining the EC phenotype (Supplementary Fig. S9) and they are degradable. iPSC-derived ECs were main-
tained in culture for 3 days while PCL nanofilms were immersed in culture medium for the same period of time 
(Fig. 7a). Platelet activation was measured by the flow cytometric quantification of CD62P (P-selectin) expres-
sion40. CD62P is a component of the α-granule membrane of resting platelets that translocates to the surface 
in consequence of platelet activation. Tyrode’s buffer diluted blood was incubated for 1 h with the cells and/or 
surfaces, afterwards blood was stained for CD61 to identify platelets and CD62P to identify activated platelets40.
As expected, thrombin induced a strong platelet activation (Fig. 7b.2). PCL nanofilms had no significant 
effect in platelet activation, as the percentage of CD62P+ platelets (4.8 ± 0.6%) was similar to TCPS (4.7 ± 0.4%) 
(Fig. 7c). AELCs alone did not activate platelets. Furthermore, AELCs in culture on PCL nanofilms did not induce 
(4.8 ± 0.2%) platelet activation.
Discussion
This study describes a protocol to derive arterial or venous-like ECs in chemically defined conditions by the mod-
ulation of VEGF signaling pathway and reports EC functional properties either in monoculture or after culture in 
a scaffold with mechanical properties similar to blood vessels.
Although recent studies have documented the differentiation of iPSCs into arterial/venous ECs6,12,13,16; only 
some protocols were performed in serum-free conditions6,13,16. In this study, the differentiation of iPSCs into 
arterial/venous ECs was performed in two steps in chemically defined medium. The protocol is based on the use 
of BMP4 and FGF-β to induce mesoderm formation followed by VEGF and Tβ4 to drive the differentiation into 
endothelial precursor cells (CD31pos/KDRpos/VE-cadmed/EphB2neg/COUP-TFneg). The obtained EPCs were then 
differentiated into arterial or venous-like ECs by the use of a high and low concentration of VEGF, respectively. 
During the submission of this work, two studies have demonstrated the derivation of arterial and venous ECs 
in serum-free culture medium from iPSCs13,16. In both studies, VEGF pathway among other signaling pathways 
including AMPc, WNT, FGF2, insulin, BMP4 and PDGF-BB have been regulated for arteriovenous specification. 
Our protocol has the advantage of simplicity by the regulation of a single signaling pathway to obtain AELCs and 
VELCs. For 1 million undifferentiated iPSCs we could obtain 7.5 million of AELCs or VELCs after 20 days of 
differentiation, while previous protocols obtained 1.7 million AELCs after 6 days13 or 4 million AELCs after 10 
days16 from the same number of undifferentiated iPSCs. Moreover, the cells obtained in this work (arterial and 
venous-like ECs) were characterized functionally at a level that was not demonstrated in previous studies. Such 
characterization is relevant for their final biomedical application.
VEGF signaling has been used to modulate the specification of ECs, under serum-free conditions. Previous 
studies have used a combination of factors (VEGF, insulin and BMP)13, AMPc16 or VEGF6 for the arteriovenous 
specification. Although the modulation of VEGF signaling has been used in a previous study, it was unclear 
the number of ECs obtained at the end of the protocol6. VEGF signaling modulates EC specification by acting 
upstream of Notch signaling, a gateway for EC specification32.
Arterial and venous ECs have different properties. Venous endothelium is more adhesive for leukocytes than 
arterial endothelium31. We found a trend for higher adhesion of THP1 monocyte cells in VELCs than in AELCs 
and HUVECs than HUAECs treated with TNF-α, suggesting that functionally VELCs are closer to a venous phe-
notype and AELCs are closer to an arterial phenotype31,32. Moreover, VELCs showed a slightly higher expression 
of E-selectin than AELCs, which makes sense taking into account that E-selectin is an adhesion molecule that 
mediates initial attachment of monocytes41. In addition, the response of arterial and venous ECs to vasoactive 
agents has subtle differences in terms of TEER. For example, thrombin decreases TEER for an extended period in 
AELCs/HUAECs than in VELCs/HUVECs.
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Figure 6. Inflammatory profile of ECs cultured in nanofilms. (a) mRNA levels of ICAM-1 and E-Selectin in 
ECs cultured on different substrates for 72 h. Expression of ICAM-1 and E-Selectin was normalized by GAPDH 
and expressed relatively to the levels before platting (n = 6). (b) mRNA levels of ICAM-1 and E-Selectin in ECs 
cultured on different substrates for 72 h and then activated with TNF-α (10 ng/ml) for 6 h, as evaluated by qRT-
PCR. Results are expressed as fold increase relative to non-treated cells (n = 3). (c) Flow cytometry analyses 
of ICAM-1 expression in ECs before (dark blue) and after (red) treatment with TNF-α (10 ng/ml) for 24 h. 
Percentages shown were calculated based on the basal levels of ICAM-1 (n = 3). In (a,b) statistical analyses 
were performed by Kruskal-Wallis test followed by a Dunn’s multiple comparisons  test. *p < 0.5, **p < 0.1, 
***p < 0.001, p**** < 0.0001. Results are mean ± SEM.
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Both AELCs and VELCs show signs of immaturity in response to pro-inflammatory molecules. AELCs or 
VELCs exposed to TNF-α highly upregulate the expression of ICAM-1 but not the levels of E-selectin or VCAM-
1. These results suggest that the iPSC-derived ECs are immature in terms of inflammatory response relatively 
to somatic ECs. Similar results have been reported previously for ECs derived from hESCs42 and from mouse 
ESCs43. In recent studies reporting the derivation of arterial and venous ECs from iPSCs, no characterization 
was provided about their reactivity to pro-inflammatory molecules6,13. However, a previous work in ECs derived 
from iPSCs in serum-containing medium showed that iPSC-derived ECs were competent as somatic ECs in 
the response to pro-inflammatory molecules44. It is possible that the functional immaturity of our EC subtypes 
might be connected with the differentiation conditions in the absence of serum and thus additional factors may 
be needed for the terminal differentiation of the cells. Yet, the inflammatory immaturity of AELCs and VELCs 
may be an opportunity in the context of cell transplantation. Indeed, the low inflammatory response of AELCs or 
VELCs may facilitate their integration with the host tissue as observed in previous vascular grafts45. In addition, 
an attenuation of vascular inflammation may decrease the risk of vascular calcification46, a risk associated to the 
vascular grafts47; however, this issue deserves further investigation.
Blood contact with polymeric synthetic materials typically leads to pro-coagulant or pro-inflammatory 
responses and also to ECs activation48. Our results show that the PCL and PDMS nanofilms did not induce a 
pro-inflammatory profile in iPSC-derived ECs and somatic ECs. In addition, we also found that neither PCL 
nanofilms nor iPSC-derived AELCs (alone or together) induced CD62P (platelet surface P-selectin) translo-
cation to platelets surface in human blood after incubation with those surfaces. P-selectin cross-links platelets 
Figure 7. Hemocompatibility of nanofilms seeded with iPSCs-derived ECs. (a) AELCs were maintained 
in culture for 3 days. PCL nanofilms were maintained in the same conditions. Human blood was incubated 
for 90 min at 37 °C with the cells and/or nanofilms, and TCPS. (b) Flow cytometry analysis of blood after 
incubation. (b.1) FSC:SSC plot showing the gating of platelets. (b.2) Analysis of CD62P in human blood platelet 
population before and after incubation with thrombin. (c) Analyses of CD62P positive events in human blood 
platelet population after incubation with TCPS, AELCs and PCL nanofilms with or without AELCs. Results are 
mean ± SEM (n = 3).
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and leukocytes and is a major mediator of platelet-leukocyte aggregate formation, thereby upregulating release 
of proinflammatory cytokines and adhesion to endothelium40. These data suggest that both nanofilms and 
iPS-derived ECs used in this study are hemocompatible.
iPSC-derived ECs adhered to nanofilms, proliferated and formed a monolayer. In terms of cell adhesion, 
AELCs and VELCs showed lower adhesion in the nanofilms than in TCPS. This was probably due to the lower 
elastic modulus value of the nanofilms (approximately 1 MPa) in comparison with TCPS (in the order of GPa)49. 
Previous studies suggest that for some cell types cellular adhesion is reduced on softer substrates50. In terms of cell 
viability and proliferation, iPSC-derived ECs showed similar behavior on nanofilms and TCPS. Regarding cell 
monolayer formation, iPSC-derived ECs were able to organize in a monolayer on top of the nanofilms, which is 
important for their barrier function. We found that VE-cadherin expression, measured by analysis of fluorescence 
mean intensity, was higher in ECs cultured in PCL nanofilms. Since VE-cadherin plays a role in the cohesion of 
intercellular junctions, this suggests that cells cultured on top of the PCL nanofilms have ticker junctions in com-
parison to the ones formed on PDMS nanofilms.
In conclusion, we have derived arterial- or venous-like ECs in chemically defined conditions by the modula-
tion of VEGF signaling pathway. We further show that these cells share functional properties of somatic ECs such 
as response to vasoactive agents and do not induce platelet coagulation; however, they have significant differences 
in their inflammatory profile, either in monoculture or after culture in a scaffold with mechanical properties 
similar to blood vessels.
Methods
A Supplementary materials and methods section is provided in Supplementary Information.
Cell lines and culture conditions. Both iPSCs (K2-iPSC, derived from human cord blood)46 and hESCs 
(clone H9, from WiCell) were cultured in standard conditions (see supplementary information) before differ-
entiation studies. HUVECs (Lonza), HUAECs (Lonza) were used between passage 2 (P2) and passage 4 (P4) 
HUVECs where acquired from Lonza at P1 and P2, HUAECs at P2. HCAECs (Innoprot) were used at passage 
P1 and P2.
Differentiation of hipsCs into eCs. hiPSCs were incubated with collagenase type IV (1 mg/ml; 
Gibco) for 45–60 min, cell aggregates were washed in culture medium, mechanically dissociated and plated in 
fibronectin-coated (Calbiochem, Merck chemicals) petri dishes with a chemically-defined medium (CDM)23: 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Gibco)- Ham’s F12 Nutrient Mixture (F12) (Gibco, [1/1 (v/v)], 
BSA fraction V (5 mg/ml; Sigma), insulin (7 mg/ml; Sigma), transferrin (15 mg/ml; Sigma) and Pen/Strep (50 U/
ml, Lonza). The following supplements were added to CDM according to the scheme in Supplementary Fig. 1: 
bone morphogenetic protein 4 (BMP-4; 10 or 50 ng/ml; Peprotech), fibroblast growth factor-β (FGF-β; 20 ng/ml; 
Peprotech), vascular endothelial growth factor 165 (VEGF; 50 ng/ml; Peprotech) and thymosin β4 (Tβ4; 100 ng/
ml; Caslo peptide synthesis)3,20. After 10 days of culture, cells were harvested with non-enzymatic cell dissociation 
buffer (Gibco, Life Technologies) and labeled with an antibody against CD31 conjugated with magnetic beads 
(Miltenyi Biotec). Labeled cells were separated from CD31− populations using a LS column (Miltenyi Biotec), 
followed by a second purification step using a MS column (Miltenyi Biotec). CD31+ enrichment was confirmed 
by flow cytometry analyses using a different anti-CD31 antibody (WM59; eBiosciences). Isolated cells (passage 0) 
were initially plated in 24 well plates (30–50,000 cells per well) coated with 0.1% gelatin with endothelial serum 
free medium (ESFM) (Life Technologies) supplemented with the TGF β-inhibitory molecule SB431542 (10 µM; 
Tocris) and VEGF (10 or 50 ng/ml) for 4 passages.
Methods for flow cytometry, immunofluorescence, qRT-PCR analyses, endothelial cell function (capillary-like 
networks on Matrigel and uptake of Dil-Ac-LDL) may be found in detail in Supplementary Materials and 
Methods section in Supplementary Information.
Quantification of COUP-TFII positive cells in iPSC-derived ECs. COUP-TFII expression was moni-
tored by immunofluorescence in iPSC-derived ECs, HUVECs (positive control) and HUAECs (negative control). 
Image acquisition was performed in a High Content Analysis (HCA) microscope (GE Healthcare, Life Sciences) 
(See Supplementary Methods).
Monocyte- EC adhesion assay. HUVECs, HUAECs and iPSCs derived-ECs were cultured until conflu-
ence. Cells were treated with TNF-α (10 ng/ml, Peprotech) for 6 h, afterwards, cells were co-cultured with CFSE 
loaded THP1 cells (See Supplementary Methods).
Expression of ICAM-1, E-Selectin and VCAM-1. HUVECs, HUAECs and iPSCs derived-ECs were 
treated with TNF-α (10 ng/ml, Peprotech) for 24 h and analyzed by flow cytometry (See Supplementary Methods).
Intracellular Ca2+ variation measurements. HUVECs, HUAECs and iPSC-derived ECs were incubated 
with acetoxymethyl (AM, 10 μM) derivative FURA-2/AM (1 mM in DMSO, Molecular Probes). Fluorescence 
measurements in response to thrombin or prostaglandin E2 were done using a microplate fluorescence reader 
(See Supplementary Methods).
trans-endothelial electrical resistance (teeR) measurements. Cells were plated in Matrigel (1:48) 
coated polycarbonate membrane transwell® inserts (Corning, 3401). The resistance of the monolayer was meas-
ured by a Millicell ERS-2 Voltohmmeter (Merck Millipore) after the addition of the stimuli (See Supplementary 
Methods).
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Nitric oxide (No) production assay. The ECs were seeded on a 0.1% gelatin-coated 24-well plate (1 × 105 
cells/well). For this experiment AELCs and VELCs were maintained in EGM2 (Lonza) medium supplemented 
with SB431542 (10 µM; Tocris) and VEGF (50 or 10 ng/ml, respectively) until confluence. HUVECs were cultured 
in EGM-2 medium (Lonza). HCAECs were cultured in endothelial cell growth medium MV-2 (Promocell). Three 
days later, the media of all four cells was changed to fresh DMEM, low glucose, pyruvate, no glutamine, no phenol 
red (Gibco®, 11880-036) media containing DAF-FM (1 µM, Life Technologies). Cells were cultured for 30 min 
and then incubated with fresh media for an additional 15 min to allow complete de-esterification of the intracel-
lular diacetates. Cells were then harvested for flow cytometry analysis. DAF-FM is non-fluorescent until it reacts 
with NO to form a fluorescent benzotriazole. The flow cytometry analyses were done in a BD Accuri C6 and the 
data analyses performed by FlowJo_V10 software.
Cell culture under flow. A suspension of cells (30 µL, 5.5 × 105 cells/channel) was added to each channel of 
a microfluidic system (µ-Slides, Ibidi) and allowed to flow inside by capillary force. After 4 h, a confluent cell layer 
was formed, which was then perfused with medium at a flow rate of 5 or 12 dyn/cm2, using an Ibidi pump system 
(perfusion set RED, µSlide VI 0.4). AELCs and VLECs were cultivated in ESFM (Life Technologies) supplemented 
with SB431542 (10 µM; Tocris) and VEGF (50 or 10 ng/ml, respectively). HUVECs and HUAECs were cultured 
in EGM-2 (Lonza). Cells were fixed and immunostained for VE-cadherin after 24 h of perfusion. The width and 
length of the cells were measured by Image J software.
Preparation of nanofilms based scaffolds. Nanofilms were prepared from poly(caprolactone) (PCL, 
Mw = 80,000, Sigma), poly(L-lactic acid) (PLLA, Mw = 60,000, Sigma) and poly(dimethylsiloxane) (PDMS, 
Sylgard® 184 Silicone elastomer kit, Dow Corning). PCL and PLLA were dissolved in chloroform at different 
concentrations (10, 20 and 50 mg/ml). PDMS was mixed in different proportions with the curing agent [1/10, 
1/20 and 1/30 (w/w)]. Nanofilms were prepared in two steps and immobilized in cell crown inserts (Scaffdex) to 
allow cell culture (see Supplementary Methods).
See Supplementary information for Methods for the characterization of nanofilms.
Cell counting in nanofilms. 4 h after cell plating, cells were stained with Hoechst (0.25 µg/ml in PBS, 
Molecular Probes for 15 min. Cells were then washed (2x) and maintained in medium. Cells were visualized 
under a fluorescence microscope and images were acquired using the AxoVision software. Each experimental 
condition was analyzed in triplicate and a minimum of 6 fields were acquired. Cell nuclei were counted using the 
ImageJ.
Presto Blue cell viability assay. Cells cultured for 4 or 72 h were incubated with Presto Blue cell viability 
reagent (Molecular Probes) for 2 h at 37 °C. Fluorescence (excitation: 560 nm; emission: 590 nm) was measured 
by a microplate reader (SYNERGY H1, BIOTEK).
Effect of nanofilms and iPSC-derived ECs on platelet activation. Human peripheral blood was col-
lected (with donors informed consent) in citrate tubes and, in less than 1 h, diluted with Tyrode’s buffer (TB) 
(10 mM HEPES, 137 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 12 mM NaHCO3, 0.4 mM Na2HPO4, 0.35% (w/v) 
BSA and 5.5 mM glucose) in the ratio of 1:10, at room temperature. The diluted blood (500 μL) was added to the 
cells and/or surfaces and incubated for 90 min at 37 °C. After incubation, samples (25 μL) were transferred to 
cytometer tubes containing TB (50 μL), CD61-PerCP (BD Biosciences) (20 μL, for platelet discrimination) and 
CD62P-PE (BD Biosciences) (20 μL, for platelet activation). Thrombin (10 UI/ml, Sigma–Aldrich) was used as 
a positive control. All samples were incubated for 30 min at RT, in the dark. After incubation, TB (500 μL) was 
added to each sample. Afterwards, samples were fixed with 2% paraformaldehyde/PBS and kept at 4 °C until they 
were analyzed with the flow cytometer.
statistical analyses. Results were analyzed by GraphPad Prism 6 (version 6.01) (GraphPad Software, La 
Jolla USA) software. We performed D’Agostino Pearson omnibus normality test and Shapiro-Wilk normality 
test in GraphPad. The results that did not pass normality test and/or with low sampling were analyzed using a 
non-parametric test. Sample pairs were analyzed with the Mann-Whitney’s test. Multiple samples were evaluated 
by Kruskal-Wallis test followed by a Dunn’s multiple comparison’s test (unless otherwise stated) to evaluate the 
statistical differences (P ≤ 0.05) among all samples or between samples and controls, respectively. All error bars 
are standard error of the mean (SEM).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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